6.01
Schlusskurs vom Vortag:
$6.10
Offen:
$6.07
24-Stunden-Volumen:
40,785
Relative Volume:
0.09
Marktkapitalisierung:
$76.80M
Einnahmen:
$134.00K
Nettoeinkommen (Verlust:
$-33.51M
KGV:
-1.8738
EPS:
-3.2074
Netto-Cashflow:
$-18.15M
1W Leistung:
-5.13%
1M Leistung:
+10.28%
6M Leistung:
-2.12%
1J Leistung:
+54.10%
Clene Inc Stock (CLNN) Company Profile
Firmenname
Clene Inc
Sektor
Branche
Telefon
801-676-9695
Adresse
6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY
Compare CLNN vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
CLNN
Clene Inc
|
6.01 | 78.65M | 134.00K | -33.51M | -18.15M | -3.2074 |
|
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Clene Inc Stock (CLNN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-10-04 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-07-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-05-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-09-28 | Eingeleitet | Oppenheimer | Outperform |
Clene Inc Aktie (CLNN) Neueste Nachrichten
Clene Inc.(NasdaqCM: CLNN) added to Russell Microcap Value Benchmark Index - marketscreener.com
Clene Inc.(NasdaqCM: CLNN) added to Russell Microcap Index - marketscreener.com
CLNN Stock Rises 8% – Here’s What The FDA Update Means For Clene’s ALS Treatment - Stocktwits
Enterprise value to EBITDA forward of Clene Inc. – NASDAQ:CLNN - TradingView
Price to earnings forward of Clene Inc. – NASDAQ:CLNN - TradingView
Price to earnings forward of Clene Inc. – BOATS:CLNN - TradingView
Clene Inc Actuals & Estimates (NASDAQ:CLNN) - TradingView
Enterprise value to EBITDA forward of Clene Inc. – BOATS:CLNN - TradingView
Enterprise value to EBIT forward of Clene Inc. – BOATS:CLNN - TradingView
Enterprise value to revenue forward of Clene Inc. – BOATS:CLNN - TradingView
CLNN Forecast — Price Target — Prediction for 2027 - TradingView
Clene Inc. (CLNN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Clene Inc. (CLNN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CLNN Q1 2026 Earnings: Clinical-Stage Biotech Delivers Narrower-Than-Expected Loss Despite No RevenueROA Comparison - dars.gov.et
Clene Inc. (CLNN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Clene Inc. (CLNNW) Institutional Confidence - TradingKey
Clene Inc. (CLNNW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Clene Inc. (CLNNW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Clene Inc. (CLNNW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Clene Inc. (CLNNW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Clene Inc. (CLNNW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year? - Yahoo Finance
Clene Inc. (CLNN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Clene Inc. (CLNNW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Clene Inc. (CLNN) Institutional Confidence - TradingKey
Clene Inc. (CLNN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Clene Inc. (CLNNW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Clene Inc. (CLNNW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Clene Inc. (CLNN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Clene Inc. (CLNN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Clene Inc. (CLNN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Clene (CLNN) Chief Science Officer receives 45,000-share stock option grant - Stock Titan
Clene (CLNN) CEO receives 65,000 stock options at $5.53 exercise price - Stock Titan
Clene (CLNN) grants CFO 15,000 stock options at $5.53 strike - Stock Titan
Clene Inc. (CLNN) Gains 5.6% as Shares Approach Key ResistanceOversold Bounce Ideas - newsline.com
Clene stock jumps after FDA opens door to accelerated approval for ALS drug - MSN
TruckMountForums acquires Bane-Clene Corporation, uniting two fam - The National Law Review
TruckMountForums acquires Bane-Clene Corporation, uniting two family-owned pillars of the professional - EIN News
Clene (CLNN) may find a bottom soon, here's why you should buy the stock now - MSN
CLNN Q1 2026 Earnings: EPS Beats Expectations Amid No Revenue, Stock DeclinesOne-Time Loss Impact - newsline.com
Clene (CLNN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
CLNN Q1 2026 Earnings: EPS Surprises to the Upside as Company Focuses on Clinical MilestonesBasic EPS Analysis - dars.gov.et
CLNN Q1 2026 Earnings: Significant EPS Beat But Stock SlidesSpecial Dividend Alert - newsline.com
CLNNClene Inc Stock Price and Quote - Finviz
CLNN Technical Analysis & Stock Price Forecast - Intellectia AI
Clene Inc. (CLNN) Shares Slide 2.24% as Stock Tests Key Support LevelsThrowback Trade - thelegaladvocate.com
CLNN Q1 2026 Earnings: EPS Beat Driven by Cost Control Amid No RevenueTangible Book Value - newsline.com
CLNN stock falls after Roth labels accelerated approval for ALS drug a 'long shot' - MSN
CLNN stock rises 8% – here’s what the FDA update means for Clene’s ALS treatment - MSN
Clene Inc. Files Form 8-K with SEC Detailing Company Information and Common Stock Listing on NASDAQ - Minichart
Clene extends note maturity and amends stock plan following annual meeting - Investing.com
Finanzdaten der Clene Inc-Aktie (CLNN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Clene Inc-Aktie (CLNN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Ugwumba Chidozie | 10% Owner |
May 11 '26 |
Sale |
6.75 |
22,177 |
149,695 |
176,713 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):